A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat’s development and patent literature review and is b...

Descrición completa

Detalles Bibliográficos

Principais autores:	Mazen Almehmadi, Mamdouh Allahyani, Ahad Amer Alsaiari, Mohammed Kanan Alshammari, Abrar Saleh Alharbi, Khansa Hamza Hussain, Lojain Ibrahim Alsubaihi, Mehnaz Kamal, Shahad Saleh Alotaibi, Atheer Nasser Alotaibi, Afeefah Awaid Aldhafeeri, Mohd Imran
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2022-08-01
Series:	Viruses
Assuntos:	Tecovirimat SIGA-246 TPOXX orthopoxvirus monkeypox patents
Acceso en liña:	https://www.mdpi.com/1999-4915/14/9/1870
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!